Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT2022 in Healthy Chinese Subjects
NCT05518695Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2022 in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Dose limiting toxicity at 7 days. Started Jun 2022; status: completed.
02
Drugs
BAT2022
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05518695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518695.